S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
NASDAQ:PHVS

Pharvaris News Headlines

$17.25
+0.23 (+1.35%)
(As of 05/13/2022 03:59 PM ET)
Add
Compare
Today's Range
$17.25
$18.00
50-Day Range
$16.35
$18.63
52-Week Range
$13.14
$23.00
Volume
4,100 shs
Average Volume
13,324 shs
Market Capitalization
$549.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.42
Get Pharvaris News Delivered to You Automatically

Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Pharvaris Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PHVS
News Sentiment

0.37

0.48

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PHVS Articles
This Week

5

0

PHVS Articles
Average Week



Pharvaris (NASDAQ:PHVS) News Headlines Today

SourceHeadline
seekingalpha.com logoPharvaris GAAP EPS of -€0.48
seekingalpha.com - May 13 at 9:04 PM
investing.com logoPharvaris Reports Q1 EPS of EUR ($0.48), Provides Business Highlights
investing.com - May 11 at 1:14 PM
finance.yahoo.com logoPharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights
finance.yahoo.com - May 11 at 1:14 PM
finance.yahoo.com logoPharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer
finance.yahoo.com - May 11 at 1:14 PM
finance.yahoo.com logoPharvaris to Participate in BofA Securities 2022 Healthcare Conference
finance.yahoo.com - May 5 at 7:01 PM
finance.yahoo.com logoCompanies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth
finance.yahoo.com - May 4 at 3:06 PM
MarketBeat logoPharvaris (NASDAQ:PHVS) Shares Gap Down to $18.00
americanbankingnews.com - May 1 at 3:44 AM
finance.yahoo.com logoPharvaris to Participate in Upcoming April Investor Conferences
finance.yahoo.com - April 6 at 4:56 PM
seekingalpha.com logoPharvaris GAAP EPS of -€0.41
seekingalpha.com - March 30 at 8:20 PM
finance.yahoo.com logoPharvaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
finance.yahoo.com - March 29 at 8:27 AM
seekingalpha.com logoPharvaris bradykinin-mediated angioedema treatment granted FDA Orphan Drug status
seekingalpha.com - March 18 at 8:15 PM
finance.yahoo.com logoPharvaris to Participate in Upcoming March Investor Conferences
finance.yahoo.com - March 3 at 4:27 PM
finance.yahoo.com logoIs Henry Schein (HSIC) Outperforming Other Medical Stocks This Year?
finance.yahoo.com - February 25 at 2:29 PM
finance.yahoo.com logoPharvaris to Participate in 11th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 9 at 8:44 AM
nasdaq.com logoPharvaris N.V. Ordinary Shares (PHVS)
nasdaq.com - January 20 at 8:18 PM
finance.yahoo.com logoPharvaris Announces Changes to its Board of Directors
finance.yahoo.com - December 7 at 9:25 AM
finance.yahoo.com logoPharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights
finance.yahoo.com - November 10 at 1:11 PM
finance.yahoo.com logoWe're Hopeful That Pharvaris (NASDAQ:PHVS) Will Use Its Cash Wisely
finance.yahoo.com - November 2 at 3:02 PM
finance.yahoo.com logoPharvaris to Participate in Upcoming September Investor Conferences
finance.yahoo.com - September 3 at 9:38 AM
finance.yahoo.com logoPharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights
finance.yahoo.com - July 30 at 8:32 AM
finance.yahoo.com logoPharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021
finance.yahoo.com - July 1 at 7:17 AM
sg.finance.yahoo.com logoBitcoin Holds Short-Term Support; Faces Resistance at $40K
sg.finance.yahoo.com - June 13 at 12:31 PM
finance.yahoo.com logoPharvaris Announces Annual Meeting of Shareholders
finance.yahoo.com - June 11 at 8:06 AM
finance.yahoo.com logoPharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE, at 12th C1 Inhibitor Deficiency and Angioedema Workshop
finance.yahoo.com - June 4 at 8:22 AM
finance.yahoo.com logoPharvaris Reports First Quarter 2021 Financial Results and Provides Business Highlights
finance.yahoo.com - May 26 at 10:06 AM
finance.yahoo.com logoPharvaris Appoints Wim Souverijns, Ph.D., as Chief Community Engagement & Commercial Officer
finance.yahoo.com - May 12 at 10:56 AM
finance.yahoo.com logoWhat Type Of Shareholders Own The Most Number of Pharvaris B.V. (NASDAQ:PHVS) Shares?
finance.yahoo.com - May 6 at 4:56 PM
nasdaq.com logoWe're Hopeful That Pharvaris B.V (NASDAQ:PHVS) Will Use Its Cash Wisely
nasdaq.com - May 6 at 11:56 AM
finance.yahoo.com logoPharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights
finance.yahoo.com - April 30 at 1:50 AM
finance.yahoo.com logoPharvaris Announces FDA Acceptance of IND Application for Prophylactic Treatment of HAE Using PHVS416
finance.yahoo.com - April 21 at 12:26 PM
finance.yahoo.com logoPharvaris Announces Closing of Initial Public Offering
finance.yahoo.com - March 9 at 9:33 AM
finance.yahoo.com logoPharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI Annual Meeting
finance.yahoo.com - March 9 at 9:33 AM
finance.yahoo.com logoPharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE
finance.yahoo.com - March 9 at 9:33 AM
finance.yahoo.com logoPharvaris to Participate in BioCapital Europe
finance.yahoo.com - March 9 at 9:33 AM
Get Pharvaris News Delivered to You Automatically

Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.